About ANI Pharmaceuticals, Inc.
https://www.anipharmaceuticals.comANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations.
CEO
Nikhil Lalwani
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-07-18 | Reverse | 1:6 |
| 2012-06-04 | Reverse | 1:6 |
ETFs Holding This Stock
XSMH.TO
Weight:0.09%
Shares:1.07M
IJR.AX
Weight:0.09%
Shares:1.07M
VTS.AX
Weight:0.00%
Shares:585.27K
Summary
Showing Top 3 of 171
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:2.66M
Value:$226.87M
BLACKROCK, INC.
Shares:2.55M
Value:$217.68M
VANGUARD GROUP INC
Shares:1.28M
Value:$109.1M
Summary
Showing Top 3 of 322
About ANI Pharmaceuticals, Inc.
https://www.anipharmaceuticals.comANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $227.81M ▲ | $88.96M ▼ | $24.13M ▲ | 10.59% ▲ | $1.19 ▲ | $61.16M ▲ |
| Q2-2025 | $211.37M ▲ | $122.86M ▲ | $8.55M ▼ | 4.04% ▼ | $0.37 ▼ | $39.24M ▼ |
| Q1-2025 | $197.12M ▲ | $97.89M ▼ | $15.68M ▲ | 7.95% ▲ | $0.7 ▲ | $48.36M ▲ |
| Q4-2024 | $190.57M ▲ | $114.67M ▲ | $-10.28M ▲ | -5.39% ▲ | $-0.55 ▲ | $14.85M ▲ |
| Q3-2024 | $148.33M | $105.78M | $-24.17M | -16.29% | $-1.27 | $-13.42M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $262.61M ▲ | $1.41B ▲ | $902.34M ▲ | $505.82M ▲ |
| Q2-2025 | $223.51M ▲ | $1.34B ▲ | $881.39M ▲ | $461.61M ▲ |
| Q1-2025 | $155.19M ▲ | $1.29B ▲ | $848.96M ▼ | $443.47M ▲ |
| Q4-2024 | $151.17M ▼ | $1.28B ▼ | $855.17M ▼ | $428.53M ▼ |
| Q3-2024 | $153.28M | $1.29B | $856.58M | $430.8M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $26.62M ▲ | $44.05M ▼ | $-6.16M ▲ | $6.34M ▲ | $44.81M ▼ | $37.89M ▼ |
| Q2-2025 | $8.55M ▼ | $75.81M ▲ | $-6.91M ▲ | $-1.75M ▲ | $68M ▲ | $68.9M ▲ |
| Q1-2025 | $15.68M ▲ | $34.99M ▲ | $-19.85M ▼ | $-9.91M ▼ | $4.94M ▲ | $15.14M ▲ |
| Q4-2024 | $-10.28M ▲ | $15.86M ▲ | $-10.68M ▲ | $-4.91M ▼ | $-123K ▲ | $13.38M ▲ |
| Q3-2024 | $-24.17M | $12.47M | $-398.52M | $291.03M | $-95.09M | $7.66M |
Revenue by Products
| Product | Q3-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Sales of Established Brands | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $30.00M ▲ |
 Sales of rare disease pharmaceutical products | $0 ▲ | $120.00M ▲ | $100.00M ▼ | $70.00M ▼ |
 Total Sales of Generics and Other | $0 ▲ | $100.00M ▲ | $90.00M ▼ | $100.00M ▲ |
 Generics Established Brands and Other | $90.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Rare Disease | $60.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q2-2024 | Q1-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 UNITED STATES | $140.00M ▲ | $140.00M ▲ | $150.00M ▲ | $180.00M ▲ |
CEO
Nikhil Lalwani
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-07-18 | Reverse | 1:6 |
| 2012-06-04 | Reverse | 1:6 |
ETFs Holding This Stock
XSMH.TO
Weight:0.09%
Shares:1.07M
IJR.AX
Weight:0.09%
Shares:1.07M
VTS.AX
Weight:0.00%
Shares:585.27K
Summary
Showing Top 3 of 171
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:2.66M
Value:$226.87M
BLACKROCK, INC.
Shares:2.55M
Value:$217.68M
VANGUARD GROUP INC
Shares:1.28M
Value:$109.1M
Summary
Showing Top 3 of 322